NHI
Recent news mentioning NHI
- — Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
- — Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
- — Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
- — Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
- — Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
- — Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure
- — BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
- — C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme
- — NHI to Participate in the BofA Securities 2026 Global Real Estate Conference; Updates Pipeline
- — TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
- — Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
- — Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Appears alongside
Browse the full archive →